Receptor News and Research

RSS

PET imaging reveals molecular mechanism behind ketamine's antidepressant effects

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond adequately to conventional antidepressant therapies.

6 Mar 2026

Engineered lettuce may turn injectable GLP-1 therapies into oral pills

Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor agonists. Initially approved by the FDA for the treatment of type 2 diabetes, they have since also transformed the therapeutic landscape of obesity and weight management.

6 Mar 2026

Single dose of CAR-astrocyte therapy halves amyloid levels in mice brains

The new generation of Alzheimer's disease drugs - the first proven to change the course of the disease - typically extend independent living for patients by 10 months.

6 Mar 2026

New compound shows promise in protecting the liver from damage after small bowel surgery

When parts of the small intestine are diseased or die, the treatment can involve surgically removing the affected tissue.

6 Mar 2026

A review of methionine dependency in modern cancer therapy

Methionine restriction (MR) has shown significant promise in cancer therapy because it targets the unique methionine dependency of many tumors. However, despite extensive research on MR, a clear synthesis of preclinical findings and their translation into clinical settings is lacking. This review aims to address this gap by consolidating existing evidence, identifying challenges, and highlighting opportunities for advancing MR as a viable cancer treatment strategy.

6 Mar 2026

Drug combination shows greater weight loss while preserving muscle mass

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue.

5 Mar 2026

Single injection may help the heart heal after heart attack

For people who have survived a heart attack, the notion of one shot in the arm to help the heart heal, for weeks after, may seem far‑fetched. But thanks to a team of researchers, including a Texas A&M University professor, that's exactly what could happen.

5 Mar 2026

Repurposed kidney drug finerenone shows promise in treating premature ovarian insufficiency

Premature ovarian insufficiency (POI) is a clinically significant cause of infertility that affects between 1 to 3% of women of childbearing age.

5 Mar 2026

Long COVID taste loss tied to reduced expression of key taste genes

The study identifies molecular changes in taste receptor cells as a potential cause of persistent taste dysfunction in long COVID-19, impacting quality of life.

5 Mar 2026

Novel gene regulation therapy passes key clinical milestone

Groundbreaking Phase 1/2a clinical trials co-led by Linda Laux, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, show that the first gene regulation treatment for epilepsy is safe and well tolerated by patients with Dravet syndrome for whom antiseizure medications are not effective.

4 Mar 2026

Mapping the year-one weight trajectory after stopping GLP-1s

A year after stopping taking weight loss drugs such as Ozempic and Wegovy, people regain, on average, 60% of their lost weight – but beyond this, their weight regain plateaus, with individuals managing to keep off 25% of the weight lost to treatment, say researchers at the University of Cambridge.

4 Mar 2026

GLP-1 drugs may be effective at treating and preventing substance use disorders

Researchers at Washington University School of Medicine in St. Louis show in a new study that GLP-1 medications may be effective at treating and preventing substance use disorders across all major addictive substances studied, suggesting these drugs target a common biological pathway underlying addiction.

4 Mar 2026

Nearly 70 weeks after infection, long COVID patients show no detectable inflammation in blood tests

A controlled Norwegian case-control study examined circulating biomarkers of inflammation and neuronal injury in people with long COVID about 69 weeks after infection. The researchers found no significant differences in systemic inflammatory or neuroinjury markers compared with recovered controls after statistical correction.

4 Mar 2026

Enhancing myelination may help sustain therapeutic effects of psychedelic-assisted PTSD treatment

Post-traumatic stress disorder (PTSD) is not only characterized by strongly encoded traumatic memories, but also by disrupted coordination across brain networks.

4 Mar 2026

Mathematical model identifies how estrogen protects women from high blood pressure

High blood pressure, or hypertension, affects more than one billion people worldwide and is a leading cause of heart disease and stroke.

4 Mar 2026

Iron found essential for growth and survival of beta cells

An international team of scientists, led by researchers from the Free University of Brussels (VUB) and UZ Brussel, has made a major breakthrough in the study of how our bodies maintain healthy blood sugar levels.

3 Mar 2026

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging dual, triple, and oral agents may further expand treatment options and improve outcomes across obesity, type 2 diabetes, and related metabolic diseases.

3 Mar 2026